Top

Published in:

01-10-2013 | Research

A Collaborative Nationwide Lymphoma Study in Lebanon: Incidence of Various Subtypes and Analysis of Associations with Viruses

Authors: Zaher K. Otrock, Jad Saab, Georges Aftimos, Fady Nasr, Fadi S. Farhat, Saad Khairallah, Gérard Abadjian, Marwan Ghosn, Hassan Sidani, Ahmad Ibrahim, Ayman Tawil, Claude Ghorra, Zarouhie Meguerian, Walid Mokaddem, Walid Dayeh, Ziad Salem, Georges Chahine, Nizar Bitar, Anas Mugharbel, Joseph Makdessi, Christina Khater, Mirna El Hajj, Dany Abi Gerges, Charles Sfeir, Joseph Kattan, Khaled Ibrahim, Michel Saade, Hussein Sadek, Rami A. Mahfouz, Mohamed A. Kharfan-Dabaja, Ghazi Zaatari, Ali Bazarbachi

Published in: Pathology & Oncology Research | Issue 4/2013

Abstract

Incidence of various Hodgkin (HL) and non-Hodgkin lymphoma (NHL) subtypes and association with viruses in Lebanon are not known. We undertook a nationwide study of 272 patients diagnosed with lymphoma in 2007. HL comprised 32.7 % (n = 89) of cases while NHL represented 67.3 % (n = 183). Consistent with the literature, nodular sclerosis was the most predominant HL subtype (n = 57/89). Among NHL, B-cell NHL represented 88 % (n = 161/183), T-cell NHL 9 % (n = 17/183), whereas in 2.7 % it was not classifiable. The B-cell NHL comprised predominantly diffuse large B-cell lymphoma (46 %) and follicular lymphoma (23 %). 81 cases were reviewed by a panel of pathologists with 87.6 % concordance rate. Serology was negative for hepatitis C in 122 tested cases. HIV was positive in 2 cases. Two adult T-cell leukemia/lymphoma were HTLV-I positive. EBV IgG were positive in 88.5 % of cases. 38 EBV seropositive cases [27 NHL (24 B-cell, 3 T-cell) and 11 HL] were studied for EBV genome expression using EBV-encoded RNA (EBER)-in situ hybridization. EBER expression was positive in 8 (21 %) cases (6 HL, 2 T-cell NHL). The distribution of lymphoma subtypes in Lebanon appears similar to that of Western countries. The high rate of EBV positivity in HL and T-cell lymphoma by EBER deserves further investigation.

Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107(1):265–276. doi:10.1182/blood-2005-06-2508 PubMedCrossRef

Roman E, Smith AG (2011) Epidemiology of lymphomas. Histopathology 58(1):4–14. doi:10.1111/j.1365-2559.2010.03696.x PubMedCrossRef

Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A (2010) The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol 148(5):739–753. doi:10.1111/j.1365-2141.2009.08010.x PubMedCrossRef

Cancer Facts and Figures 2010 (Accessed February 16, 2011)

Ekstrom-Smedby K (2006) Epidemiology and etiology of non-Hodgkin lymphoma—a review. Acta Oncol 45(3):258–271. doi:10.1080/02841860500531682 PubMedCrossRef

Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, Qian DG, Velankar M, Nathwani BN, Fong TL (1997) Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 127(6):423–428PubMedCrossRef

Muller AM, Ihorst G, Mertelsmann R, Engelhardt M (2005) Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 84(1):1–12. doi:10.1007/s00277-004-0939-7 PubMedCrossRef

Suarez F, Lortholary O, Hermine O, Lecuit M (2006) Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 107(8):3034–3044. doi:10.1182/blood-2005-09-3679 PubMedCrossRef

Yamaguchi K, Takatsuki K (1993) Adult T cell leukaemia–lymphoma. Baillieres Clin Haematol 6(4):899–915PubMedCrossRef

10.

Baris D, Zahm SH (2000) Epidemiology of lymphomas. Curr Opin Oncol 12(5):383–394PubMedCrossRef

11.

Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, Jack A, McNally R, Morgan G, de Sanjose S, Tumino R, Vornanen M (1999) The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 35(4):627–633PubMedCrossRef

12.

Bosetti C, Levi F, Ferlay J, Lucchini F, Negri E, La Vecchia C (2008) Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic? Int J Cancer 123(8):1917–1923. doi:10.1002/ijc.23722 PubMedCrossRef

13.

Greiner TC, Medeiros LJ, Jaffe ES (1995) Non-Hodgkin’s lymphoma. Cancer 75(1 Suppl):370–380PubMedCrossRef

14.

Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ (2002) Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 94(16):1204–1210PubMedCrossRef

15.

Clarke CA, Glaser SL (2002) Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 94(7):2015–2023. doi:10.1002/cncr.10403 PubMedCrossRef

16.

Carreon JD, Morton LM, Devesa SS, Clarke CA, Gomez SL, Glaser SL, Sakoda LC, Linet MS, Wang SS (2008) Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996–2004. Cancer Causes Control 19(10):1171–1181. doi:10.1007/s10552-008-9184-z PubMedCrossRef

17.

Nakatsuka S, Aozasa K (2006) Epidemiology and pathologic features of Hodgkin lymphoma. Int J Hematol 83(5):391–397. doi:10.1532/IJH97.05184 PubMedCrossRef

18.

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRef

19.

Mueller N (1994) Another view of the epidemiology of non-Hodgkin’s lymphoma. Oncology (Williston Park) 8(9):83

20.

Glaser SL, Swartz WG (1990) Time trends in Hodgkin’s disease incidence. The role of diagnostic accuracy. Cancer 66(10):2196–2204PubMedCrossRef

21.

Jaffe ES, Harris N, Stein H, Vardiman JW (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon

22.

Shamseddine A, Sibai AM, Gehchan N, Rahal B, El-Saghir N, Ghosn M, Aftimos G, Chamsuddine N, Seoud M (2004) Cancer incidence in postwar Lebanon: findings from the first national population-based registry, 1998. Ann Epidemiol 14(9):663–668. doi:10.1016/j.annepidem.2003.12.002 PubMedCrossRef

23.

Castella A, Joshi S, Raaschou T, Mason N (2001) Pattern of malignant lymphoma in the United Arab Emirates—a histopathologic and immunologic study in 208 native patients. Acta Oncol 40(5):660–664PubMedCrossRef

24.

Bamanikar S, Thunold S, Devi KR, Bamanikar A (1995) The pattern of malignant lymphoma in Oman. J Trop Med Hyg 98(5):351–354PubMed

25.

Akhtar SS, Haque IU, Wafa SM, El-Saka H, Saroor AM, Nadrah HM (2009) Malignant lymphoma in Al-Qassim, Saudi Arabia, reclassified according to the WHO classification. Saudi Med J 30(5):677–681PubMed

26.

Haddadin WJ (2005) Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification. Ann Saudi Med 25(5):398–403PubMed

27.

Shome DK, George SM, Al-Hilli F, Satir AA (2004) Spectrum of malignant lymphomas in Bahrain. Leitmotif of a regional pattern. Saudi Med J 25(2):164–167PubMed

28.

Temmim L, Baker H, Al-Jarallah M, Manguno H, Madda JP, Sinowatz F (2004) Clinical characteristics and pathological classification of non-Hodgkin’s lymphoma in Kuwait. Results of a collaborative study with the International Lymphoma Study Group (ILSG). Leuk Lymphoma 45(9):1865–1871. doi:10.1080/10428190410001697386 PubMedCrossRef

29.

Kadin ME, Berard CW, Nanba K, Wakasa H (1983) Lymphoproliferative diseases in Japan and Western countries: proceedings of the United States–Japan Seminar, September 6 and 7, 1982, in Seattle, Washington. Hum Pathol 14(9):745–772PubMedCrossRef

30.

Ho FC, Todd D, Loke SL, Ng RP, Khoo RK (1984) Clinico-pathological features of malignant lymphomas in 294 Hong Kong Chinese patients, retrospective study covering an eight-year period. Int J Cancer 34(2):143–148PubMedCrossRef

31.

Ko YH, Kim CW, Park CS, Jang HK, Lee SS, Kim SH, Ree HJ, Lee JD, Kim SW, Huh JR (1998) REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European–American lymphoma. Cancer 83(4):806–812. doi:10.1002/(SICI)1097-0142(19980815)83:4<806::AID-CNCR26>3.0.CO;2-V PubMedCrossRef

32.

Shih LY, Liang DC (1991) Non-Hodgkin’s lymphomas in Asia. Hematol Oncol Clin N Am 5(5):983–1001

33.

Ameen R, Sajnani KP, Albassami A, Refaat S (2010) Frequencies of non-Hodgkin’s lymphoma subtypes in Kuwait: comparisons between different ethnic groups. Ann Hematol 89(2):179–184. doi:10.1007/s00277-009-0801-z PubMedCrossRef

34.

Al-Kuraya K, Narayanappa R, Al-Dayel F, El-Solh H, Ezzat A, Ismail H, Belgaumi A, Bavi P, Atizado V, Sauter G, Simon R (2006) Epstein-Barr virus infection is not the sole cause of high prevalence for Hodgkin’s lymphoma in Saudi Arabia. Leuk Lymphoma 47(4):707–713. doi:10.1080/10428190500286879 PubMedCrossRef

35.

Allemani C, Sant M, De Angelis R, Marcos-Gragera R, Coebergh JW (2006) Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer 107(2):352–360. doi:10.1002/cncr.21995 PubMedCrossRef

36.

Makar RR, Saji T, Junaid TA (2003) Epstein–Barr virus expression in Hodgkin’s lymphoma in Kuwait. Pathol Oncol Res 9(3):159–165PubMedCrossRef

37.

Al-Shemmari SH, Al-Humood S, Ameen R, Kamlesh S, Nemec J, Varghese A (2004) Hodgkin’s disease: Kuwait experience. Med Princ Pract 13(4):201–205. doi:10.1159/000078316 PubMedCrossRef

38.

Proctor IE, McNamara C, Rodriguez-Justo M, Isaacson PG, Ramsay A (2011) Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network. J Clin Oncol 29(11):1431–1435. doi:10.1200/JCO.2010.31.2223 PubMedCrossRef

39.

Lester JF, Dojcinov SD, Attanoos RL, O’Brien CJ, Maughan TS, Toy ET, Poynton CH (2003) The clinical impact of expert pathological review on lymphoma management: a regional experience. Br J Haematol 123(3):463–468PubMedCrossRef

40.

Ferri C, Caracciolo F, Zignego AL, La Civita L, Monti M, Longombardo G, Lombardini F, Greco F, Capochiani E, Mazzoni A et al (1994) Hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Br J Haematol 88(2):392–394PubMedCrossRef

41.

Pozzato G, Mazzaro C, Crovatto M, Modolo ML, Ceselli S, Mazzi G, Sulfaro S, Franzin F, Tulissi P, Moretti M et al (1994) Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 84(9):3047–3053PubMed

42.

Dal Maso L, Franceschi S (2006) Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 15(11):2078–2085. doi:10.1158/1055-9965.EPI-06-0308 PubMedCrossRef

43.

Hausfater P, Cacoub P, Sterkers Y, Thibault V, Amoura Z, Nguyen L, Ghillani P, Leblond V, Piette JC (2001) Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France. Am J Hematol 67(3):168–171. doi:10.1002/ajh.1101 PubMedCrossRef

44.

Udomsakdi-Auewarakul C, Auewarakul P, Sukpanichnant S, Muangsup W (2000) Hepatitis C virus infection in patients with non-Hodgkin lymphoma in Thailand. Blood 95(11):3640–3641PubMed

45.

Salem Z, Nuwaiyri-Salti N, Ramlawi F, Ramia S (2003) Hepatitis C virus infection in Lebanese patients with B-cell non-Hodgkin’s lymphoma. Eur J Epidemiol 18(3):251–253PubMedCrossRef

46.

Irani-Hakime N, Musharrafieh U, Samaha H, Almawi WY (2006) Prevalence of antibodies against hepatitis B virus and hepatitis C virus among blood donors in Lebanon, 1997–2003. Am J Infect Control 34(4):241–243. doi:10.1016/j.ajic.2005.06.009 PubMedCrossRef

47.

Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H (1977) Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50(3):481–492PubMed

48.

Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de The H, El-Sabban ME, Hermine O (2004) New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol 5(11):664–672. doi:10.1016/S1470-2045(04)01608-0 PubMedCrossRef

49.

Bitar N, Hajj HE, Houmani Z, Sabbah A, Otrock ZK, Mahfouz R, Zaatari G, Bazarbachi A (2009) Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon. Transfusion 49(9):1859–1864. doi:10.1111/j.1537-2995.2009.02223.x PubMedCrossRef

50.

Spano JP, Atlan D, Breau JL, Farge D (2002) AIDS and non-AIDS-related malignancies: a new vexing challenge in HIV-positive patients. Part I: Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma. Eur J Intern Med 13(3):170–179PubMedCrossRef

51.

Dal Maso L, Serraino D, Franceschi S (2001) Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer 37(10):1188–1201PubMedCrossRef

52.

Rabkin CS (1994) Epidemiology of AIDS-related malignancies. Curr Opin Oncol 6(5):492–496PubMedCrossRef

53.

Carbone A, Gloghini A, Dotti G (2008) EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 13(5):577–585. doi:10.1634/theoncologist.2008-0036 PubMedCrossRef

54.

Jones JF, Shurin S, Abramowsky C, Tubbs RR, Sciotto CG, Wahl R, Sands J, Gottman D, Katz BZ, Sklar J (1988) T-cell lymphomas containing Epstein–Barr viral DNA in patients with chronic Epstein–Barr virus infections. N Engl J Med 318(12):733–741. doi:10.1056/NEJM198803243181203 PubMedCrossRef

55.

Rezk SA, Weiss LM (2007) Epstein–Barr virus-associated lymphoproliferative disorders. Hum Pathol 38(9):1293–1304. doi:10.1016/j.humpath.2007.05.020 PubMedCrossRef

56.

Shibata D, Hansmann ML, Weiss LM, Nathwani BN (1991) Epstein–Barr virus infections and Hodgkin’s disease: a study of fixed tissues using the polymerase chain reaction. Hum Pathol 22(12):1262–1267PubMedCrossRef

57.

Evans AS, Gutensohn NM (1984) A population-based case–control study of EBV and other viral antibodies among persons with Hodgkin’s disease and their siblings. Int J Cancer 34(2):149–157PubMedCrossRef

58.

Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS (1991) Expression of Epstein–Barr virus latent gene products in tumour cells of Hodgkin’s disease. Lancet 337(8737):320–322PubMedCrossRef

59.

Anagnostopoulos I, Herbst H, Niedobitek G, Stein H (1989) Demonstration of monoclonal EBV genomes in Hodgkin’s disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 74(2):810–816PubMed

60.

Staratschek-Jox A, Kotkowski S, Belge G, Rudiger T, Bullerdiek J, Diehl V, Wolf J (2000) Detection of Epstein–Barr virus in Hodgkin-Reed-Sternberg cells: no evidence for the persistence of integrated viral fragments inLatent membrane protein-1 (LMP-1)-negative classical Hodgkin’s disease. Am J Pathol 156(1):209–216. doi:10.1016/S0002-9440(10)64721-9 PubMedCrossRef

61.

Khan G, Coates PJ, Kangro HO, Slavin G (1992) Epstein Barr virus (EBV) encoded small RNAs: targets for detection by in situ hybridisation with oligonucleotide probes. J Clin Pathol 45(7):616–620PubMedCrossRef

62.

Khan G (2009) Screening for Epstein–Barr virus in Hodgkin’s lymphoma. Methods Mol Biol 511:311–322. doi:10.1007/978-1-59745-447-6_13 PubMedCrossRef

63.

Enblad G, Sandvej K, Sundstrom C, Pallesen G, Glimelius B (1999) Epstein–Barr virus distribution in Hodgkin’s disease in an unselected Swedish population. Acta Oncol 38(4):425–429PubMedCrossRef

64.

Chang KL, Albujar PF, Chen YY, Johnson RM, Weiss LM (1993) High prevalence of Epstein–Barr virus in the Reed–Sternberg cells of Hodgkin’s disease occurring in Peru. Blood 81(2):496–501PubMed

65.

Katebi M, Sharifi N, Tarhini M, Otrock ZK, Bazarbachi A, Kchour G (2008) Frequency of Epstein–Barr virus expression in various histological subtypes of Hodgkin’s lymphoma. Histopathology 52(6):775–777. doi:10.1111/j.1365-2559.2008.03019.x PubMedCrossRef

66.

Mourad W, Alsohaibani MO, Saddik M, Bazerbashi S (1998) Epstein–Barr virus expression in Hodgkin’s disease: correlation with histologic subtypes and T and B lymphocyte distribution. Ann Saudi Med 18(4):296–300PubMed

67.

Almasri NM, Khalidi HS (2004) Epstein–Barr virus expression in Hodgkin’s disease in Jordan. Saudi Med J 25(6):770–775PubMed

68.

Levine PH, Pallesen G, Ebbesen P, Harris N, Evans AS, Mueller N (1994) Evaluation of Epstein–Barr virus antibody patterns and detection of viral markers in the biopsies of patients with Hodgkin’s disease. Int J Cancer 59(1):48–50PubMedCrossRef

69.

Enblad G, Sandvej K, Lennette E, Sundstrom C, Klein G, Glimelius B, Pallesen G (1997) Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed–Sternberg cells of patients with Hodgkin’s disease. Int J Cancer 72(3):394–397. doi:10.1002/(SICI)1097-0215(19970729)72:3<394::AID-IJC3>3.0.CO;2-K PubMedCrossRef

70.

Axdorph U, Porwit-MacDonald A, Sjoberg J, Grimfors G, Ekman M, Wang W, Biberfeld P, Bjorkholm M (1999) Epstein–Barr virus expression in Hodgkin’s disease in relation to patient characteristics, serum factors and blood lymphocyte function. Br J Cancer 81(7):1182–1187. doi:10.1038/sj.bjc.6690827 PubMedCrossRef

71.

Abdel-Fattah MM, Yassine OG (2007) Non-Hodgkin’s lymphomas in Alexandria, Egypt; incidence rates and trend study (1995–2004). Eur J Cancer Prev 16(5):479–485. doi:10.1097/01.cej.0000243858.91642.c9 PubMedCrossRef

72.

Wu XC, Andrews P, Chen VW, Groves FD (2009) Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: anatomic site and histology differences. Cancer Epidemiol 33(5):337–346. doi:10.1016/j.canep.2009.09.006 PubMedCrossRef

Title: A Collaborative Nationwide Lymphoma Study in Lebanon: Incidence of Various Subtypes and Analysis of Associations with Viruses
Authors: Zaher K. Otrock
Jad Saab
Georges Aftimos
Fady Nasr
Fadi S. Farhat
Saad Khairallah
Gérard Abadjian
Marwan Ghosn
Hassan Sidani
Ahmad Ibrahim
Ayman Tawil
Claude Ghorra
Zarouhie Meguerian
Walid Mokaddem
Walid Dayeh
Ziad Salem
Georges Chahine
Nizar Bitar
Anas Mugharbel
Joseph Makdessi
Christina Khater
Mirna El Hajj
Dany Abi Gerges
Charles Sfeir
Joseph Kattan
Khaled Ibrahim
Michel Saade
Hussein Sadek
Rami A. Mahfouz
Mohamed A. Kharfan-Dabaja
Ghazi Zaatari
Ali Bazarbachi
Publication date: 01-10-2013
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2013
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-013-9634-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Overexpression of CD73 in Prostate Cancer is Associated with Lymph Node Metastasis

Naringenin (Citrus Flavonone) Induces Growth Inhibition, Cell Cycle Arrest and Apoptosis in Human Hepatocellular Carcinoma Cells

Large Cell Lymphoma: Correlation of HIV Status and Prognosis with Differentiation Profiles Assessed by Immunophenotyping

p16INK4a Immunoprofiles of Squamous Lesions of the Uterine Cervix–Implications for the Reclassification of Atypical Immature Squamous Metaplasia

Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma

Molecular Profiling of ADAM12 and ADAM17 Genes in Human Malignant Melanoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer